FDA Grants Fast Track designation to IVS-3001, a CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma
Invectys announces U.S. Food and Drug Administration (FDA) has granted Fast Track designation to IVS-3001, its cutting-edge CAR-T cell immunotherapy targeting the rarely exploited immune checkpoint and tumor-specific antigen HLA-G.
Invectys Announces Initiation of Phase 1/2a Clinical Trial in Solid Tumors and Change in Leadership
Invectys announces it has initiated the clinical trial of its lead CAR-T program, IVS-3001, in solid tumors, as well as the appointment of Dr. Jake Kushner, M.D., as its new CEO.
Invectys to participate in project Melomanes
Melomanes is a multidisciplinary project, which aims to develop a novel combination treatment for metastatic melanoma, based on nanoparticles and CAR-T cells.
Invectys and CTMC Announce FDA Clearance of IND Application for Anti-HLA-G CAR-T Cell Therapy
FDA granted IND clearance for a Phase 1/2a clinical trial for IVS-3001, Invectys’s lead engineered anti-HLA–G CAR-T cell therapy, for the treatment of patients with solid tumors.
Invectys, MD Anderson and CTMC Announce Strategic Collaboration for CAR T Cell Therapy Development
The collaboration will build upon the HLA-G platform pioneered by Invectys to advance novel CAR T cell therapies through preclinical development with CTMC into early-phase clinical studies at MD Anderson, and bring Invectys’ technology together with the cell therapy development and manufacturing expertise of CTMC and the clinical trials expertise of MD Anderson.
Invectys, Inc. Appoints François Lescure as General Manager of its R&D Subsidiary, Invectys, SAS
Founder of MédecinDirect and former Manager of Teladoc France, Dr. Lescure is a veteran of the healthcare industry with a career spawning over more than 30 years.
Wayne A. Marasco, M.D., Ph.D. joins Invectys’ Scientific Advisory Board
Dr. Marasco brings to Invectys his pioneering expertise in the field of human antibody engineering and cellular/stem cell therapies in which he is senior author of over 175 peer reviewed publications, chapters, books and monographs and holds over 75 patents.
Invectys appoints Jian Cao, Ph.D., as Vice President, Pharmaceutical Development
Dr. Cao brings in extensive experience in biological drug development and GMP manufacturing support of IND through BLA submissions.
Invectys to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference, January 10-13, 2022
Praveen Tyle, Ph.D., Invectys Inc. President and CEO will provide an outlook for the business and its pipeline of treatments for cancer diseases and present an overview of all of Invectys’ projects to date on January 10th.
Invectys Inc. to participate in the 2022 JP Morgan Healthcare Meeting and Biotech Showcase, January 10-19, 2022
Praveen Tyle, Ph.D., Invectys Inc. President and CEO will participate in the JP Morgan Healthcare Meeting and Biotech showcase held virtually on January 10-19, 2022.
Invectys Inc. to participate in the 2021 Roth Virtual Healthcare Private Company Forum on June 28th, 2021
Praveen Tyle, Ph.D., Invectys Inc. President and CEO, and Julien Caumartin, Ph.D. CSO of Invectys SA, will participate in the Roth Virtual Healthcare Private Company Forum, on Monday, June 28th, 2021.
June, 1st, 2021 – Invectys, Inc appoints Rosemary Williams, CPA as Vice-President for Administration and Controller
Invectys Inc. annouces the nomination of Rosemary Williams, CPA as Vice-President for Administration and Controller.
May, 4, 2021 – Invectys, Inc appoints Biopharma Veteran, Praveen Tyle, PhD as President & CEO
Invectys Inc. annouces the nomination of Praveen Tyle, veteran biopharma manager, as its new CEO.
Nov, 12, 2020 – Invectys’ CARGo project garners $14.2M 2020 CPRIT Award (Cancer Prevention and Research Institute of Texas )
Invectys’ anti-HLA-G CAR-T cell project was awarded with the CPRIT Award, through which it has garnered $14.2 million.
May, 5, 2020 – Invectys: Dennis J. Purcell (Aisling Capital) join Advisory Board
Invectys Strengthens Advisory Board with the Appointment of Dennis J. Purcell, Life Sciences Industry Veteran and Founder of Aisling Capital LLC.
Feb, 4, 2020 – Invectys reports in vivo efficacy of its pan anti-tumor anti-HLA-G CAR-T cells
These results could lead to CAR-T cells more potent against solid tumors.
Jun, 18, 2019 – Invectys élu « meilleur projet – jeune entreprise » 2019 par le Board international de MATWIN
Invectys est le lauréat 2019 du prix industriel du programme MATWIN de soutien à la maturation de projets innovants en oncologie.
Oct, 29, 2018 – Invectys secures €15 million equity financing to advance lead program INVAC-1 into groundbreaking phase II clinical trial in CLL
Financing complements the €4.3 million raised in July 2017 and represents one of the largest immune-oncology financing rounds in Europe.
July 12th, 2017 – €4,3 million fundraising to initiate Phase II
After its success in Phase I, Invectys raises €4.3 million to start Phase II for its two anti-cancer vaccines.
May 24, 2017 – Invectys presents its INVAC-1 therapeutic vaccine Phase I results at ASCO in USA
Presentation of the Invectys clinical trial results on cancer patients at the most important worldwide oncology meeting taking place this year in Chicago, USA.
April 26, 2017 – Invectys at the Third International Symposium on Immunotherapy
Invectys at the Third International Symposium on Immunotherapy organised by The Institute for Cancer Vaccines & Immunotherapy (previously known as the Cancer Vaccine Institute).
Nov 29, 2016 – Medicen Paris Region and Invectys announce success of the TelVac project for the research on a cancer vaccine candidate.
The research project, led by Invectys and supported by Medicen Paris Region, improved the INVAC-1 vaccine candidate to accelerate clinical trials in solid tumor patients.
July 29, 2016 – Invectys files a patent on the acquisition of a checkpoint inhibitor for oncology
This patent covers the acquisition of antibodies against a novel immune checkpoint, aiming to unlock the immune system against the tumor.
March 18, 2016 – New success for the therapeutic vaccine INVAC-1 for patients with cancer
With 7 million raised in the last year and excellent results in terms of tolerance and innocuity, Invectys opens up new hopes in cancer immunotherapy.
Jan 21, 2016 – Invectys raises a further 7 million euros to accelerate clinical development of its therapeutic cancer vaccine
With more than 17 million euros raised in total Invectys also benefits from 850,000€ in financing from Bpifrance.
Oct 30, 2015 – Invectys starts the third dose level of its phase I clinical trial evaluating INVAC-1, an innovative anti-cancer therapeutic vaccine
A new clinical hope in cancer immunotherapy.
May 12, 2015 – Invectys Initiates Phase I Clinical Trial Evaluating INVAC-1 Therapeutic Vaccine for Cancer Patients
A new clinical hope in cancer immunotherapy.
March 30, 2015 – Invectys raises 1.7 million Euros more to finance the clinical development of its therapeutic cancer vaccine
With a total of 10 million euros raised, new premises, new labs and new equipment, Invectys is ready for the clinic.
Sept 29, 2014 – Invectys receives ANSM approval to start clinical trial for INVAC-1, its leading anticancer immunotherapy
INVAC-1 is an anticancer candidate vaccine targeting telomerase activity in cancer cells.